Weight Loss & Metabolism
Peptides studied for appetite regulation, glucose control, fat metabolism, and body composition — including GLP-1 and dual/triple agonists.
17 peptides in this category
Cagrilintide + Semaglutide
Combined amylin analog and GLP-1 research protocol studied for additive weight loss.
Semaglutide
The reference GLP-1 receptor agonist studied heavily for weight loss and glycemic control.
Tirzepatide
Dual GLP-1 + GIP agonist studied for superior glycemic and weight outcomes vs single-agonists.
Dulaglutide
Long-acting GLP-1 receptor agonist studied for glucose control and weight management.
HGH Fragment 176-191
C-terminal fragment of human growth hormone studied for lipolytic effects without affecting glucose or IGF-1.
L-Carnitine
Amino acid derivative researched for fatty-acid transport and mitochondrial energy.
Liraglutide
Daily GLP-1 receptor agonist researched for glucose control and weight loss.
MOTS-c
16-amino-acid mitochondrial-derived peptide studied as an exercise mimetic.
Retatrutide
Triple agonist studied for the most aggressive weight reduction signals in metabolic research.
5-Amino-1MQ
Small molecule NNMT inhibitor studied for fat-cell and metabolic effects.
Adipotide
Experimental peptide studied for selective destruction of fat-tissue blood supply.
AOD9604
Fragment of human growth hormone researched for fat-burning effects without glucose or IGF-1 impact.
Cagrilintide
Long-acting amylin analog studied alongside GLP-1 agonists for added satiety.
Mazdutide
Dual GLP-1/glucagon receptor agonist researched for obesity and metabolic disease.
SLU-PP-332
Small molecule (not a peptide) researched as an ERR-α/β/γ agonist exercise mimetic.
Survodutide
Dual GLP-1/Glucagon agonist researched for weight and liver outcomes.
Tesamorelin
Stabilized GHRH analog studied for visceral adipose reduction.